Podcasts about Elevate

Henry Abbott is a pioneer of sports media. Henry is an award-winning journalist and founder of TrueHoop, where he and his team cover basketball with depth and curiosity. Henry previously led ESPN's 60-person NBA digital and print team, which published several groundbreaking articles and won a National Magazine Award. His latest book is ⁠Ballistic: The New Science of Injury-Free Athletic Performance⁠, available wherever books are sold. Thank you to the sponsors of The Elevate Podcast Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠masterclass.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Framer: ⁠⁠⁠⁠framer.com/elevate⁠⁠⁠⁠ Northwest Registered Agent: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠northwestregisteredagent.com/elevatefree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Homeserve: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠homeserve.com⁠⁠⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, attorney and law professor, Matt Siembieda, joins Impact to delve into the ongoing legal saga surrounding Alec Murdaugh, particularly focusing on the implications of a recent motion to supplement the record in his appeal. They discuss the upcoming oral arguments scheduled for February 11th, where the South Carolina Supreme Court will hear Murdaugh's appeal against his murder charges. The conversation highlights the procedural aspects of the case, including the significance of credibility issues surrounding key witnesses, particularly Becky Hill, who pled guilty to perjury. Seton Tucker and Matt Harris began the Impact of Influence podcast shortly after the murders of Maggie and Paul Murdaugh. Now they cover true crime past and present from the southeast region of the U.S. Impact of Influence is part of the Evergreen Podcast Company. Look for Impact of Influence on Facebook and Youtube. Please support our sponsors Elevate your closet with Quince. Go to Quince dot com slash impact for free shipping on your order and three hundred and sixty-five -day returns Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, attorney and law professor, Matt Siembieda, joins Impact to delve into the ongoing legal saga surrounding Alec Murdaugh, particularly focusing on the implications of a recent motion to supplement the record in his appeal. They discuss the upcoming oral arguments scheduled for February 11th, where the South Carolina Supreme Court will hear Murdaugh's appeal against his murder charges. The conversation highlights the procedural aspects of the case, including the significance of credibility issues surrounding key witnesses, particularly Becky Hill, who pled guilty to perjury. Seton Tucker and Matt Harris began the Impact of Influence podcast shortly after the murders of Maggie and Paul Murdaugh. Now they cover true crime past and present from the southeast region of the U.S. Impact of Influence is part of the Evergreen Podcast Company. Look for Impact of Influence on Facebook and Youtube. Please support our sponsors Elevate your closet with Quince. Go to Quince dot com slash impact for free shipping on your order and three hundred and sixty-five -day returns Learn more about your ad choices. Visit megaphone.fm/adchoices

☀️ Crypto Gathering Miami 2026: not everyone wants the full conference sprint. That's why there's the Social Pass ($300): welcome drinks, beach party, and Drinks with @RaoulGMI LIVE

On a special episode of The Elevate Podcast, host Robert Glazer answers listener questions on the first ever Elevate Podcast Mailbag. To submit a question for a future episode, email mailbag@robertglazer.com On this episode, Robert and producer Mick Sloan tackle questions like: If you could write a letter to your 20 year old self, what would you say? How do you talk about values with your kids? What are key practices for a first-time manager, or a first-time executive? What is a professional decision that you wish you had made differently? Thank you to the sponsors of The Elevate Podcast Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠masterclass.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Framer: ⁠⁠framer.com/elevate⁠⁠ Northwest Registered Agent: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠northwestregisteredagent.com/elevatefree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Homeserve: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠homeserve.com⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Even if you are in the messy middle or space in-between, tune in to hear a few questions that will be super useful in your next season and this next year, infused with the 2026 new moon energy. If you haven't subscribed to the newsletter for exclusive events, offerings and announcements make sure you are on the newsletter here: www.KellyLynnAdams.com If you are looking for support in this season here are a few ways that are available in 2026... Private 1:1 Consulting, Advising, Coaching & Mentorship (limited availability) VIP Immersion In-Person & Virtual Experiences (1 spot remains) The Private Offer The Elevate 6 Month Mastermind is now enrolling (5 spots remain) & The Luxury Leadership Lab (waitlist is open) 30 Day VIP Accelerator CEO Reset Experience  The Inner Circle Paid Community + Movement is being elevated and upgraded, for more information message us CEO Circle Society. And if you haven't checked out The Luxury Digital Library of bite size business trainings on the website, head on over there now: www.KellyLynnAdams.com/services Make sure to subscribe to this podcast and leave a review, and share with a friend and tag us at @kellylynnadams

Join Our Online Education Community "The School of Doza" Here: https://community.schoolofdoza.com/ In this podcast episode, Nurse Doza discusses the common complaint of fatigue and offers insights into its possible causes. He emphasizes the importance of addressing fatigue, as it should not be a daily occurrence. He also recommends getting blood tests, particularly one for DHEAS, to assess adrenal function and the body's response to stress. He mentions that chronic stress, lack of sleep, and unhealthy lifestyle habits can contribute to fatigue. Nurse Doza encourages listeners to prioritize self-care, including good sleep and stress management, to improve their energy levels and overall health.   TIMESTAMPS: 00:00 START 05:50 Adrenal issues can cause fatigue. 11:46 Inflammation and fatigue are connected. 16:34 Address underlying causes of fatigue. 22:08 Check homocysteine levels for fatigue. 27:43 Sugar and inflammation decrease ATP. 32:15 Adrenal support supplement is recommended.     Looking for a boost in energy and mood? Discover Zen, MSW's premium adrenal support supplement. Packed with natural ingredients, it aids in balancing your hormones and combating fatigue. Elevate your health and regain that lost zest for life.  Click here

We're so stoked to be sitting with Jon Poff this evening!  Jon recently took ownership of Kingsnake.com and his vision for the platform is very exciting!!  Tonight, we'll be discussing all things Kingsnake, including the first national expo Kingsnakes attended in many years - the Pomona Reptile Super Show!  Don't miss this!  Make sure you subscribe to the YouTube channel!  https://reptiletalk.buzzsprout.com______________________________Reptile Talk is Sponsored by:BLACK BOX CAGESSAFE Quality Reptile Cages & Racks. Innovative housing solutions. Elevate your reptile-keeping game!**USE CODE - REPTILETALK and SAVE on your next order!!! **Website:https://bit.ly/BLKBox _______________________________RAGING RODENTS - LibertyServing the Southeast US with quality, domestically produced feeder rodents and more!  Disabled Veteran Owned and Operated!Facebook:  / ragingrodentsliberty  _______________________________KINGSNAKE.COMKingsnake is making a comeback!   A platform full of herp history and knowledge for the serious keeper/hobbyist! Website:www.kingsnake.com_______________________________FIND US ON IGhttps://bit.ly/ReptileTalkIG https://bit.ly/creepingitrealIGhttps://bit.ly/BMRIG

Stop letting fear of the wrong choice lead to the biggest mistake of all: no decision making at all. Join the conversation as host Penny Zenker sits down with neuroscientist, researcher, and keynote speaker Lorne Epstein, who consults with senior leaders on improving decision making outcomes. They dive into how to navigate today's volatile, uncertain, chaotic, and ambiguous (VUCA) world by identifying unconscious bias, the critical role of cognitive flexibility, and why you need to master your personal 'reset moment' to filter out the noise and find your signal. Lorne also shares insights on his novel psychometric assessment for teams and explains how AI can be a great advisory tool in your decision making process.Love the show? Subscribe, rate, review, and share! https://pennyzenker360.com/positive-productivity-podcast/

Our show is best watched on YouTube:https://go.www.letsgettothepoints.com/BoraBoraJoin us as we explore the ultimate travel paradise, Bora Bora, a dream vacation destination. We'll share valuable travel tips, including resort bookings vs flight redemptions. Get ready to plan your next luxurious escape!Thank you to Gary from https://www.instagram.com/ventureonpoints/ for joining us as a guest co-host!Learn about points and miles in our Elevate course and community:https://letsgettothepoints.com/elevateSerena's Bora Bora Episode:https://www.youtube.com/watch?v=V4rVGa0OrKMWhale Watching Tour:https://www.viator.com/tours/Moorea/Whale-watching/d5182-395678P1?pid=P00137785&mcid=42383&medium=linkFull Day Snorkeling Lagoon Tour:https://www.viator.com/tours/Bora-Bora/Lagoon-Service-Full-Day-Group-Tour/d5180-297962P1?pid=P00137785&mcid=42383&medium=linkHot Logic:https://amzn.to/45OuEnBCredit Card Links: http://go.www.letsgettothepoints.com/CreditCardsSign up for our newsletter:https://go.www.letsgettothepoints.com/JoinOurEmailWebsite: https://www.letsgettothepoints.com/Email: letsgettothepoints@gmail.comIG: https://www.instagram.com/letsgettothepoints/ TikTok: https://www.tiktok.com/@letsgettothepointsEXCLUSIVE TRAVEL DISCOUNT CODES:https://letsgettothepoints.com/tools/Seats.aero: Award Flight Search EngineUse Code: LETSGETPRO for $20 off the first yearhttps://seats.aero/Book Private Transport in 100+ Countries with Kiwitaxi:https://go.www.letsgettothepoints.com/KiwitaxiUse Code: LGTTP5 for 5% off all ridesSign up for Award Email Notifications from Straight To The PointsUse Code: LGTTP20 for 20% off the annual planhttps://go.www.letsgettothepoints.com/StToThePointsTravel Freely: The FREE site we use to stay organized and track our 5/24 statushttps://my.travelfreely.com/signup?bref=lgwCardPointers: Save Money and Maximize Your Spend Bonuseshttps://go.www.letsgettothepoints.com/CardPointersMaxMyPoint: Hotel Rewards CheckerUse Code: LGTTP for 20% off the first year of your Platinum Subscription https://maxmypoint.comON TODAY'S SHOW:0:00 Intro1:14 French Polynesia on Points and Miles3:29 Flights to Tahiti on Points and Miles21:01 Tahiti Hotels on Points24:44 Moorea Hotels on Points33:13 Bora Bora Hotels on Points58:00 The Best Activities in French PolynesiaDisclaimer: The content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.Advertiser Disclosure:This video may contain links through which we are compensated when you click on or are approved for offers. The information in this video was not provided by any of the companies mentioned and has not been reviewed, approved, or otherwise endorsed by any of these entities. Offers are current only at the time of the video publishing date and may have changed by the time you watch it.Let's Get To The Points is part of an affiliate sales network and receives compensation for sending traffic to partner sites, such as CardRatings. Let's Get To The Points and CardRatings may receive a commission from card issuers.This compensation may impact how and where links appear on this site. This site does not include all financial companies or all available financial offers. Terms apply to American Express benefits and offers. Enrollment may be required for select American Express benefits and offers. Visit americanexpress.com to learn more.Opinions expressed here are the author's alone, not those of any bank, credit card issuer, hotel, airline, or other entity. This content has not been reviewed, approved or otherwise endorsed by any of the entities included within the post. The content of this video is accurate as of the posting date. Some of the offers mentioned may no longer be available.

In this podcast, experts Sara A. Hurvitz, MD, FACP, Michelle Melisko, MD, and Paolo Tarantino, MD, PhD, discuss approaches to maintenance and subsequent lines of therapy for patients with HER2+ advanced breast cancer, including those with CNS metastases.

Amanda Ripley has extensively studied anti-fragility and resilience. She is an investigative Journalist of three books, including High Conflict, The Smartest Kids In The World and a her latest, The Unthinkable: Who Survives When Disaster Strikes, and Why. She has reported for The Atlantic, Politico, the Washington Post, Time Magazine and other outlets, and her work has helped Time win two National Magazine Awards. Amanda joined host Robert Glazer on the Elevate Podcast to discuss reforming the education system, building resilience, and much more. Thank you to the sponsors of The Elevate Podcast Mizzen & Main: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mizzenandmain.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Promo Code: elevate20) Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠masterclass.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Northwest Registered Agent: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠northwestregisteredagent.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠ Homeserve: ⁠⁠⁠⁠⁠⁠⁠⁠homeserve.com⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

See more here: https://karenswain.com/elevate-2026/ Where do we belong? Why do we have such a drive to belong to certain groups ideas, ideologies, religions societies, people? We will Look at this today on ELEVATE - WAKING THE QUANTUM SELF. JOIN us in the live chat. Please send us your show ideas and questions here: https://karenswain.com/connect/ Live Show Date & Times: Wednesdays - @ 6 - 7 pm ET -@ 5 - 6 CT - @ 4 - 5 pm MT - 3 - 4 pm PT USA/CA Thursdays - @ 10 - 11 am AEST - 9 - 10 am QLD Australia 2025 Appreciate KAren's work Awakening Consciousness? THANK YOU for your Support for the content. Share your appreciation on this link https://www.paypal.me/KArenASwain LINKS; Kristin Mismash Website: https://www.kristinmismash.com/ ATP- Media: https://karenswain.com/listen/ Host: KAren Swain https://karenswain.com See our links https://linktr.ee/KArenSwain Join our Facebook Groups https://www.facebook.com/groups/TheInnerSanctumSessions https://www.facebook.com/groups/AwakeningEmpowermentNetwork ELEVATE Consciousness is a show on UPRN which started in 2025. Live conversations and Q & A with KAren Swain and friends around the awareness shift that is waking our quantum realities. Also conversations on HOT topics in the Spiritual and Consciousness genre. Audience participation - Please send us your questions. #Belong #belonging #socialconditioning #hypnosis #spiritguides #ascension #consciousness #5dconnection KAren Swain Awakening & Expanding Consciousness

In this episode, Swamiji redefines success through Krishna's lens, showing that true achievement is not about defeating others but about elevating oneself. He begins with the story of a little girl at her school sports day who, despite finishing last, was praised by her father for being ahead of many others. The lesson: success is relative, and each person runs a unique race.  Swamiji explains that worldly measures of success — medals, rankings, comparisons — often trap us in competition and dissatisfaction. Krishna, however, teaches that the real race is internal: to conquer the mind and rise above its weaknesses. Quoting the Bhagavad Gita (6.5), Swamiji highlights: “Elevate yourself through the power of your mind, and do not degrade yourself. For the mind can be your best friend, or your worst enemy.”  He emphasizes that success which pleases God is measured by self‑improvement, humility, and sincerity in effort. Every setback becomes a lesson, every step forward an offering to the Divine. When we stop comparing ourselves to others and focus on becoming better than our past selves, there is no failure — only growth.  This teaching matters because it liberates seekers from the anxiety of competition and redirects them toward inner progress. By following Krishna's definition of success, we cultivate resilience, peace, and devotion — achievements that truly please God.  About Swami Mukundananda: Swami Mukundananda is a renowned spiritual leader, Vedic scholar, Bhakti saint, best‑selling author, and an international authority on the subject of mind management. He is the founder of the unique yogic system called JKYog. Swamiji holds distinguished degrees in Engineering and Management from two of India's most prestigious institutions—IIT and IIM. Having taken the renounced order of life (sanyas), he is the senior disciple of Jagadguru Shree Kripaluji Maharaj, and has been sharing Vedic wisdom across the globe for decades. 

Attendance at the Ontario Certified Crop Advisor Association (CCA) annual meeting this week topped 250 CCAs and industry representatives — that's a crowd executive director Susan Fitzgerald hasn't seen since pre-COVID. Fitzgerald says a large turnout for an organization with total membership of 650 signals a resurgence in in-person engagement this winter. “It’s a good... Read More

☀️ Crypto Gathering Miami 2026: not everyone wants the full conference sprint. That's why there's the Social Pass ($300): welcome drinks, beach party, and Drinks with @RaoulGMI LIVE

https://bit.ly/4aazkY7

Full Gospel Center's Pastor Rick Leonardi preaching the message "Genesis - Part 18" on 01/14/2026 referencing Genesis 24:1-67.

Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

A big change is coming to Elevate. In this episode, Heather and I walk through the experiment, the data, and the clarity that led to a major business decision — and why it actually serves photographers better.What to Listen ForWhy experiments matter more than perfectionHow action creates clarity fastWhat the data actually revealedThe downside of staying underpricedWhy value and price must alignHow pricing impacts client behaviorWhat fear-free decisions feel likeThe role belief plays in growthWhy commitment changes outcomesBig decisions don't have to feel heavy or dramatic. Sometimes they feel clean, calm, and obvious. Tune in to hear why this one did.Join us inside Elevate now and lock in the current price for as long as you stay in the program. https://flourishacademy.mykajabi.com/elevateJOIN THE PARTY: Connect with us on Instagram Explore valuable pet photography resources here Discover effective pricing and sales strategies for all portrait photographers. Ready to grow your business? Elevate helps you do just that. Check out our recommended gear and favorite books.

What if the greatest leadership breakthroughs begin with owning your truth? In this conversation with Joe Machicote about his book, Own Thy Stuff, we explore what it really means to take responsibility for your impact—on yourself, your relationships, and the culture at large. Joe shares deeply personal and practical insights from decades of leadership, all rooted in his lifelong commitment to leaving every person and situation better than he found it. You'll hear stories that will challenge the way you think about communication, presence, and the stories you create in your own mind. You'll also discover the power leaders have to create spaces of trust, especially during grief, conflict, and moments of emotional strain. Joe's candor about his own journey, including profound personal loss, opens the door to a compassionate and courageous view of leadership. He offers simple, meaningful practices that help you slow down, listen more deeply, and act with intention so you can strengthen culture, relationships, and your own self-mastery. Joe is Chief Culture Officer at Premier, where he partners with the CEO, the Executive Team, and other stakeholders across the company. His role is to enhance and formalize a mission-driven culture of equal opportunity, high performance, and belonging. Joe has served in senior HR positions over the past 30+ years. His new book, Own Thy Stuff: The Continuous  Improvement Journey to Becoming an Extraordinary Human Being,  captures his most important insights and lessons from life and work:  You'll discover: Why “owning your stuff” creates trust and credibilityHow to support team members experiencing grief with compassion, not fixesA simple mindset shift that transforms assumptions into clarityPractices for increasing presence and reducing distractionThe difference between mentoring and sponsoring—and why both matterCheck out all the episodesLeave a review on Apple PodcastsConnect with Meredith on LinkedInFollow Meredith on TwitterDownload the free ebook Listen Like a Pro

https://bit.ly/meetwithAPP

Uncover the latest trends in book marketing innovation straight from three industry disruptors who are reshaping the author's journey. Juliet Clark sits down with Kathleen Kaiser of the ProBookLaunch; Desireé Duffy, founder of the PR agency Black Château and The BookFest; and Jared Kuritz, CEO of Strategies Public Relations and CMO of the cutting-edge audio platform Zoundy. They tackle the shift in publishing, beginning with the explosive growth of the audiobook market, which has now surpassed e-books in sales. They also explore new platforms like Zoundy that offer authors unprecedented marketing and list-building control. Learn why Kathleen asserts that marketing is a science and how her agency uses AI to automate media kit creation. Desireé highlights the resurgence of listicle articles and the enduring importance of human connection, even as technology speeds up. Finally, Jared breaks down the essential business model every author needs. He covers the critical mindset shift: building your community, not just selling your book, starting 12 to 24 months in advance.Love the show? Subscribe, rate, review, and share! https://superbrandpublishing.com/podcast/

What does the future of leadership really require from us leaders?While Susan Hobson and Tracey Allen are away, we're bringing you a special 2026 highlight reel episode of The Leadership Launchpad Podcast - The Legacy Edition—a curated compilation of powerful insights from past conversations with world-class experts who joined us throughout 2025.This episode brings together some of the most thought-provoking perspectives on where leadership is heading and what leaders will need to develop this year to stay relevant, resilient, and effective in the years ahead.How the future of leadership is shifting from performance alone to consciousness and self-awarenessWhy adaptability, curiosity, and emotional intelligence are becoming essential leadership skillsWhat conscious leadership means in times of rapid change, AI disruption, and uncertaintyWhy leaders must learn to navigate paradox, tension, and complexity rather than avoid itHow intentional daily practices build the self-awareness required to lead wellHow empathy and understanding in culture will lead future of leadershipThis episode is not a prediction based on trends alone—it's a reflection drawn from lived experience, research, and real leadership conversations. Consider it an invitation to pause, listen, and reflect on how you want to lead into the future.Whether you're leading an organization, a team, a family, or yourself, this compilation offers insight into the inner development required to meet what's coming next.

Dec 30, Spencer and Monique Tepe were found dead in their home. Their two young children were home but unharmed. There was no sign of a robbery or a break in. The Columbus Police Department was tight lipped and the speculation became intense. January 10, an arrest was made of Monique's ex-husband, Michael David McKee. McKee is a vascular surgeon near Chicago. Impact brings you the latest on this tragedy. Bo Barton joined Impact to discuss how these types of investigations work. Barton worked for years with the South Carolina Law Enforcement division in various roles including as a homicide detective. Barton became a certified profiler and at the time he was one of only 108 certified profilers on the planet. Seton Tucker and Matt Harris began the Impact of Influence podcast shortly after the murders of Maggie and Paul Murdaugh. Now they cover true crime past and present from the southeast region of the U.S. Impact of Influence is part of the Evergreen Podcast Company. Look for Impact of Influence on Facebook and Youtube. Please support our sponsors Elevate your closet with Quince. Go to Quince dot com slash impact for free shipping on your order and three hundred and sixty-five -day returns Learn more about your ad choices. Visit megaphone.fm/adchoices

☀️ Crypto Gathering Miami 2026: not everyone wants the full conference sprint. That's why there's the Social Pass ($300): welcome drinks, beach party, and Drinks with @RaoulGMI LIVE

Tune in to hear 3 simple statements that will increase your energy, vibration and income. If you haven't subscribed to the newsletter for exclusive events, offerings and announcements make sure you are on the newsletter here: www.KellyLynnAdams.com If you are looking for support in this season here are a few ways that are available in 2026... Private 1:1 Consulting, Advising, Coaching & Mentorship (limited availability) VIP Immersion In-Person & Virtual Experiences (1 spot remains) The Elevate 6 Month Mastermind & The Luxury Leadership Lab (waitlists are now open) 30 Day VIP Accelerator CEO Reset Experience  The Inner Circle Paid Community + Movement is being elevated and upgraded, for more information message us CEO Circle Society. And if you haven't checked out The Luxury Digital Library of bite size business trainings on the website, head on over there now: www.KellyLynnAdams.com/services Make sure to subscribe to this podcast and leave a review, and share with a friend and tag us at @kellylynnadams

In this week's episode of Elevate the Day, we are sharing personal experiences and scriptural principles on how to navigate feelings of hopelessness and anxiety.Fear and anxiety are universal feelings that everyone experiences at some point in their lives. The key is to acknowledge these feelings without letting them dictate our actions.Taking Proactive Steps It's important to make a conscious decision to address these feelings rather than succumbing to them. Sometimes it just takes a reminder of God's faithfulness to uplift our spirits.Journaling: A Powerful Tool One effective method to overcome overwhelm is journaling. Writing down your thoughts and feelings can help clarify what's bothering you and often reveals that the issues may not be as overwhelming as they seem. Engaging with Scripture Turning to Scripture is a vital part of overcoming fear and anxiety. Reading the Bible or listening to uplifting teachings can remind us of God's promises and faithfulness. Community Support Being part of a supportive church or group of friends can make a world of difference on tough days. Simple gestures like a hug from a loved one can provide comfort and remind us that we are cared for. Taking Control of Your Environment Be mindful of the influences in our lives. If social media or certain shows contribute to feelings of negativity, it's wise to limit exposure to them. Surrounding yourself with positive, uplifting people can significantly impact your mental state. Dealing with fear and anxiety is a journey that requires proactive measures, faith, and community support. By making a conscious effort to reach out for help, engage with scripture, and surround ourselves with positive influences, we can overcome the feelings of hopelessness that often plague us. Tags: #OvercomingFear #AnxietyRelief #Faith #CommunitySupport #Journaling #Scripture #MentalHealth #EmotionalWellness #ElevateTheDay

Full Gospel Center's Pastor Rick Leonardi preaching the message "Gospel of John - Part 42" on 01/11/2026 referencing John 12:1-11.

Well, everyone, after a much-needed hiatus, we are back!!  In this episode, Rob and I will discuss what's been going on and what the plans are for Reptile Talk in 2026.  We're so excited to be back with you all!  Make sure you subscribe to the YouTube channel!  https://reptiletalk.buzzsprout.com______________________________Reptile Talk is Sponsored by:BLACK BOX CAGESSAFE Quality Reptile Cages & Racks. Innovative housing solutions. Elevate your reptile-keeping game!**USE CODE - REPTILETALK and SAVE on your next order!!! **Website:https://bit.ly/BLKBox _______________________________RAGING RODENTS - LibertyServing the Southeast US with quality, domestically produced feeder rodents and more!  Disabled Veteran Owned and Operated!Facebook:  / ragingrodentsliberty  _______________________________KINGSNAKE.COMKingsnake is making a comeback!   A platform full of herp history and knowledge for the serious keeper/hobbyist! Website:www.kingsnake.com_______________________________FIND US ON IGhttps://bit.ly/ReptileTalkIG https://bit.ly/creepingitrealIGhttps://bit.ly/BMRIG

Top Stories for January 10th Publish Date: January 10th PRE-ROLL: Kia Mall of Georgia From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Saturday, January 10th and Happy Birthday to Rod Stewart I’m Peyton Spurlock and here are your top stories presented by Gwinnett KIA Mall of Georgia. Affordability a top concern as lawmakers prepare for Georgia legislative session Srim Academy to host series of free seminars for young parents Christkindl Market drove 77% increase in downtown Lawrenceville visitors All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: EAGLE THEATRE STORY 1: Affordability a top concern as lawmakers prepare for Georgia legislative session When Georgia lawmakers head back to the Capitol next week, it’s all about affordability—or at least that’s the plan. House Speaker Jon Burns isn’t mincing words: “We’re laser-focused on making life affordable,” he said Wednesday, pointing a finger at property taxes for crushing the dream of homeownership. “For too many families, it’s slipping out of reach. We’ve got to fix that.” Meanwhile, Senate Republicans are eyeing income taxes. A committee led by Sen. Blake Tillery wants to nix the 5.19% tax for individuals earning under $50,000 (or $100,000 for couples) and eventually scrap it altogether by 2032. But affordability isn’t just about taxes. Rising medical costs? A mess. The end of federal health insurance subsidies? A looming crisis. Burns says the House will tackle health care, focusing on keeping doctors in Georgia by expanding residency programs. STORY 2: Srim Academy to host series of free seminars for young parents Srim Academy, a Montessori school in Norcross, is kicking off a series of free seminars for young parents—because, let’s face it, parenting is hard. Topics? Everything from potty training and screen time battles to fostering independence and getting kids to actually move their bodies. The first session, “Fostering Your Child’s Independence: Lemonade, Ladybugs and Learning,” happens Saturday, Jan. 31, at 10:30 a.m. at 5511 Williams Road. Expect 90 minutes of practical advice, hands-on activities (think crafts and cooking), and maybe even a few lightbulb moments. Led by Srim’s seasoned faculty and guests from Gwinnett Building Babies’ Brains, it’s all about building confidence—for kids and parents. Bonus: giveaways! Details? Visit www.srimacademy.com or call 678-808-9813. STORY 3: Christkindl Market drove 77% increase in downtown Lawrenceville visitors Lawrenceville’s first year hosting the Atlanta Christkindl Market? A total game-changer. Nearly 371,000 people visited the market during its debut season downtown—more than double the attendance from its Buckhead days, even with fewer open days. And here’s the kicker: 159,500 of those visitors wandered over to the Lawrenceville Square, boosting local restaurants and shops by 77% compared to 2024. Free parking, shuttles, and a glowing Winterlight Walk helped draw crowds, with visitors from 48 states. Downtown businesses saw sales jump 5–30%, and vendors reported 20–30% higher sales than the previous year. The collaboration between the city and Gwinnett County was key, with County Chairwoman Nicole Love Hendrickson adding, “This event showed what’s possible when partnerships thrive.” Lawrenceville’s officially on the holiday map. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: Ingles Markets STORY 4: 2026 Beer Chaser 5K Registration is open Whether you’re a speed demon or a beer-loving stroller, the Beer Chaser 5K is calling your name. On March 7, Suwanee Town Center Park transforms into a St. Paddy’s Day celebration with a twist—running, sipping, and plenty of green. This isn’t your average 5K. Sure, it’s a Peachtree Road Race qualifier, but it’s also a beer lover’s dream. Choose your adventure: run straight through or stop at five beer stations along the scenic Suwanee Creek Greenway. Each station features a different Georgia brewery, so your taste buds get a workout too. Not into mid-run sips? No worries. Every runner (21+) gets a full beer at the finish line. And the party doesn’t stop there—StillFire Brewing is hosting an after-party with live music, food trucks, and 25 beers on tap. Registration starts at $55 for the straight-through option or $65 if you want those beer stops. Prices go up Feb. 1, so don’t wait. Oh, and don’t forget your festive St. Paddy’s Day gear—there are prizes for best costume, best group, and best kilt. Proceeds benefit Kiwanis Charity, supporting local causes like the North Gwinnett Co-Op and Children’s Healthcare. Details? Head to SuwaneeBeerFest.com/beer-chaser-5k/. STORY 5: Lanier Islands Resort looks back at 2025, forward to an exciting 2026 Lanier Islands Resort just wrapped up a big year—its 50th anniversary—and it’s clear they’re not slowing down anytime soon. Recognized as one of Georgia’s Best Vacation Destinations, the resort is leaning into its legacy while planning some exciting upgrades for 2026. Last year was packed: a new chapel and garden for weddings, a free summer concert series, the return of Magical Nights of Lights, and even a lantern festival that drew 4,500 people. Oh, and they snagged awards from The Knot, WeddingWire, and GolfPass, among others. Looking ahead? A $3 million refresh for Legacy Lodge, a revamped golf clubhouse, and Georgia’s first lighted Par-3 course. Plus, new events like a Fall Songwriter Series. Big things are coming. We’ll be right back. Break 3: GCPL Passport STORY 6: Rep. Andrew Clyde announces 2026 Congressional Art Competition Hey, high school artists in Georgia’s Ninth District—Congressman Andrew Clyde wants *you* to show off your talent in the 2026 Congressional Art Competition. Got a creative spark? Here’s your chance to have your work displayed in the U.S. Capitol for a whole year. Submissions are due Feb. 20, and the process is simple: send a digital image of your piece first, and if you’re a finalist, drop off the physical artwork by March 13. The theme? Anything that reflects North Georgia—think landmarks, industries, or even your school. Accepted mediums include paintings, drawings, mixed media, photography, and more. Just keep it two-dimensional, under 26x26 inches framed, and under 15 pounds. Oh, and no copying or controversial content—this is about originality. Questions? Call Clyde’s Gainesville office at 470-768-6520. Let’s see what you’ve got! STORY 7: Gwinnett Chamber introduces Elevate Business series The Gwinnett Chamber is shaking things up with the launch of the Elevate Business Series (EBS)—a fresh, expanded take on their long-running Small Business Series. Starting in 2026, this revamped program is all about helping small and medium-sized businesses level up with sharper insights, practical strategies, and tools to thrive. Why the change? Simple: demand. Attendance has been climbing, industries are diversifying, and businesses are hungry for deeper, more advanced content. “Elevate reflects how far we’ve come—and where we’re going,” said Megan Lesko, the Chamber’s Senior VP of Membership. The first event? Feb. 24, featuring Media Frenzy CEO Sarah Tourville on strategic communications. We’ll have closing comments after this Break 4: Sugar Hill Ice Skating Rink Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com www.kiamallofga.com Ice Rink – Downtown Sugar Hill NewsPodcast, CurrentEvents, TopHeadlines, BreakingNews, PodcastDiscussion, PodcastNews, InDepthAnalysis, NewsAnalysis, PodcastTrending, WorldNews, LocalNews, GlobalNews, PodcastInsights, NewsBrief, PodcastUpdate, NewsRoundup, WeeklyNews, DailyNews, PodcastInterviews, HotTopics, PodcastOpinions, InvestigativeJournalism, BehindTheHeadlines, PodcastMedia, NewsStories, PodcastReports, JournalismMatters, PodcastPerspectives, NewsCommentary, PodcastListeners, NewsPodcastCommunity, NewsSource, PodcastCuration, WorldAffairs, PodcastUpdates, AudioNews, PodcastJournalism, EmergingStories, NewsFlash, PodcastConversations See omnystudio.com/listener for privacy information.

Hey y'all ! Welcome to another Friday with CWCOI ! In this week's episode, our host, Ally Yost shares a part two to our last episode, 'I wish someone told me this in my 20's.' Ally mainly focuses on and dives deep into the difference between chemistry and compatibility in relationships. "Charm is deceptive, and beauty is fleeting; but a woman who fears the Lord is to be praised." Proverbs 31:30 _____________________________________________  ☆ If you're struggling with OCD or unrelenting intrusive thoughts, NOCD can help. Book a free 15 minute call to get started: https://learn.nocd.com/CWCOI ☆ Give your skin a rest with clean, clinically tested skincare from OSEA. Use code 'COFFEE' for 10% off your first order sitewide ➤ https://oseamalibu.com ☆ Elevate your morning with Everyday Dose, coffee plus benefits. Use code 'CWCOI' for 61% off your first order ➤ https://www.everydaydose.com ☆ REP CWCOI MERCH ➤ https://allyyost.com ☆ MY BIBLE (code 'ALLYYOST' at checkout) ➤ https://hosannarevival.com/collections/beautiful-bibles/products/nlt-notetaking-bible-versailles-theme ☆ TUMBLER LINK ➤https://allyyost.com/products/travel-tumbler _____________________________________________ Connect further with us ! TikTok ➤ https://www.tiktok.com/@christwithcoffeeonice Instagram ➤ https://instagram.com/christwithcoffeeonice _____________________________________________ Connect further with Ally ! TikTok (2M) ➤ https://www.tiktok.com/@ally_yost Instagram ➤ https://www.instagram.com/ally_yost/ ShopMy ➤ https://shopmy.us/allyyost Pinterest ➤ https://www.pinterest.com/ally_yost1/_created/

Kick off 2026 strong by ditching the lazy girl era!Join Asha Christina on Quality Queen Control for the ultimate Anti-Lazy Girl Manifesto! In this empowering episode, Asha breaks down 26 transformative things she and her listeners are bringing into their winter arc for unstoppable growth in mindset, productivity, relationships, faith, and self-improvement.Discover actionable productivity tips for women, motivation strategies to rebuild discipline, goal-setting habits for 2026, and faith-based wisdom to level up your life. Whether you're rebranding your career, elevating your dating standards, or building unshakeable confidence, this manifesto is your blueprint to become the high-value queen you're meant to be.Perfect for women ready to exit lazy girl jobs, embrace hot girl winters, and manifest abundance in the new year. Let's make 2026 your most disciplined, sophisticated era yet!

In this episode of Business Coaching Secrets, Karl Bryan and Rode Dog kick off the new year by diving deep into the psychology of compounding success, handling client loss, building an irresistible brand, and the surprising power of stopping your worst habits before adding new ones. Packed with frameworks, mindsets, and strategies for scaling coaching businesses, this conversation sets a foundation for meaningful, profitable growth in 2026 and beyond. Key Topics Covered The Psychology of Compounding Karl Bryan explains how real progress in both business and personal growth follows a compounding curve—boring and slow for most of the journey, before results skyrocket. He compares doubling a penny every day to the patient grind of building new habits, networking, and acquiring skills. Managing Client Loss & Turning Pain into Fuel Drawing from personal experience, Karl reframes lost clients as vital awakenings for a coach's development, not failures. He likens the evolution to relationships, urging coaches to "build into someone no client would want to leave," reject desperation, and approach setbacks as chances to upgrade purpose and mastery. Status, Energy, and Luxury Branding in Coaching Karl discusses how "vibe" and energy—like a seasoned waiter in a top restaurant—create attraction and authority in client relationships. Coaches who hold themselves with confidence (not arrogance) and employ purposeful energy are respected, sought after, and able to retain clients long-term. Exclusivity, Scarcity & Storytelling Luxury brands like Gucci and Ferrari don't just charge more—they mean more. Karl reveals how controlled scarcity, storytelling, and identity shift the coaching value proposition from transactional to transformational. Rather than being "liked by everyone," coaches and clients win by being respected and building a brand people want to join. Zen Master Insights for Happiness & Productivity Karl shares Arthur Brooks' 4 rules for happiness and adds his own: "learning." He warns about the "death loop" of social media comparison, the dangers of technical work without meaning, and the need for deeper faith, family, genuine friendships, and personal growth. The Power of Eliminating Worst Habits First Instead of piling on new habits, Karl encourages coaches to ruthlessly cut out the most sabotaging activities—doom scrolling, excessive TV, video games, etc.—and channel freed-up energy into productive tasks. Focus is achieved more through removing distractions than forcing attention. Notable Quotes "The problem with compounding is it's not till day 25 that there's any excitement. The numbers are tiny and lame till everything takes off." "[When you lose a client], it's not the time to cry in your Cheerios—It's an awakening more than anything else." "Neediness is your enemy. Walk in like you own the place, not like you want to buy it." "Luxury branding isn't about charging more—it's about meaning more." "Focus is eliminating distractions more than it is focusing. No is a decision, yes is a responsibility." "Comparison is the thief of joy. Social media... is a death loop for happiness." Actionable Takeaways Play the Long Game With Compounding: Stick with new disciplines far past the "boring" stage; results will spike after consistency and patience. Transform Setbacks Into Upgrades: When clients leave, treat it as a wake-up call to elevate skills, boundaries, and purpose—don't focus on loss, focus on mastery. Embodied Confidence Wins Clients: Present yourself with purposeful energy and professional vibe—confidence, not arrogance, is magnetic to prospects. Engineer Scarcity & Story: Position your coaching as exclusive; tell a bigger brand story that clients aspire to join. Scarcity creates clarity and demand. Eliminate (Not Add) For Focus: List your worst habits and cut one immediately. Use freed-up time for learning, networking, or strategic work. Protect Your Mindset: Consciously avoid social media comparison and schedule time for real relationships, faith, and continual self-education. Resources Mentioned Profit Acceleration Software 2.0™ (Developed by Karl Bryan) For instant client ROI demonstrations and deeper client engagement

Click here to join us in Elevate, it's the last chance to ever get in at our current pricing. It will never be this inexpensive again and you will be grandfathered for as long as you stay.

Our show is best watched on YouTube:https://go.www.letsgettothepoints.com/USAFamilyDiscover the best family destinations in the U.S. you can book with points and miles. We break down the best flights, family-friendly hotels, and top things to do in each destination, with real-world tips for stretching your points further. We cover Hilton, Hyatt, and Marriott options to help families maximize value and travel more for less.Correction: Must be over 42" for Crown Access to the Status of LibertyThank you to Kate from https://www.instagram.com/kates_on_a_plane/ for joining us as a guest co-host!Learn about points and miles in our Elevate course and community:https://letsgettothepoints.com/elevateCredit Card Links: http://go.www.letsgettothepoints.com/CreditCardsSign up for our newsletter:https://go.www.letsgettothepoints.com/JoinOurEmailWebsite: https://www.letsgettothepoints.com/Email: letsgettothepoints@gmail.comIG: https://www.instagram.com/letsgettothepoints/ TikTok: https://www.tiktok.com/@letsgettothepointsEXCLUSIVE TRAVEL DISCOUNT CODES:https://letsgettothepoints.com/tools/Seats.aero: Award Flight Search EngineUse Code: LETSGETPRO for $20 off the first yearhttps://seats.aero/Book Private Transport in 100+ Countries with Kiwitaxi:https://go.www.letsgettothepoints.com/KiwitaxiUse Code: LGTTP5 for 5% off all ridesSign up for Award Email Notifications from Straight To The PointsUse Code: LGTTP20 for 20% off the annual planhttps://go.www.letsgettothepoints.com/StToThePointsTravel Freely: The FREE site we use to stay organized and track our 5/24 statushttps://my.travelfreely.com/signup?bref=lgwCardPointers: Save Money and Maximize Your Spend Bonuseshttps://go.www.letsgettothepoints.com/CardPointersMaxMyPoint: Hotel Rewards CheckerUse Code: LGTTP for 20% off the first year of your Platinum Subscription https://maxmypoint.comON TODAY'S SHOW:0:00 Intro1:30 The Best Family Destinations in the USA5:03 San Diego, CA on Points and Miles20:16 Washington, D.C. on Points and Miles30:22 Wilmington, NC on Points and Miles38:43 New York City on Points and Miles49:33 Hawaii on Points and Miles54:38 Albuquerque, New Mexico on Points and Miles1:00:50 Hilton All-Inclusives in the USThank you for supporting our Channel! See you every Friday with a new episode!Support this podcast: https://go.www.letsgettothepoints.com/SupportUsDisclaimer: The content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.Advertiser Disclosure:This video may contain links through which we are compensated when you click on or are approved for offers. The information in this video was not provided by any of the companies mentioned and has not been reviewed, approved, or otherwise endorsed by any of these entities. Offers are current only at the time of the video publishing date and may have changed by the time you watch it.Let's Get To The Points is part of an affiliate sales network and receives compensation for sending traffic to partner sites, such as CardRatings. Let's Get To The Points and CardRatings may receive a commission from card issuers.This compensation may impact how and where links appear on this site. This site does not include all financial companies or all available financial offers. Terms apply to American Express benefits and offers. Enrollment may be required for select American Express benefits and offers. Visit americanexpress.com to learn more.Opinions expressed here are the author's alone, not those of any bank, credit card issuer, hotel, airline, or other entity. This content has not been reviewed, approved or otherwise endorsed by any of the entities included within the post. The content of this video is accurate as of the posting date. Some of the offers mentioned may no longer be available.

Six years after Mallory Beach's tragic death in a boat crash, one lawsuit still lingers. It is the "Outrage" case against Parker's Corporation. Impact has done a few episodes on this case. In this episode the discussion revolves around a confidentiality order and a request for a gag order. In addition, a letter was released indicating how contentious this suit has become, with one podcaster mocking an involved party's "man parts" . Plus, texts reveal malicious comments made about a podcaster and an attempt to spread misinformation about that podcaster and her podcast. Seton Tucker and Matt Harris began the Impact of Influence podcast shortly after the murders of Maggie and Paul Murdaugh. Now they cover true crime past and present from the southeast region of the U.S. Impact of Influence is part of the Evergreen Podcast Company. Look for Impact of Influence on Facebook and Youtube. Please support our sponsors Elevate your closet with Quince. Go to Quince dot com slash impact for free shipping on your order and three hundred and sixty-five -day returns Learn more about your ad choices. Visit megaphone.fm/adchoices

David Heinemeier Hansson is a true innovator. He is the co-founder of Basecamp, which has been used by over 20 million people globally. He's also the founder of Hey and the creator of the transformational Ruby on Rails, an open source web framework that was used to create Basecamp, Github, Shopify, Airbnb and more. David is also a frequent writer at Hey World, the New York Times bestselling author of four books, including Rework, and even an award winning racecar driver.  In this classic episode, David joined host Robert Glazer on ⁠the Elevate Podcast⁠ to talk about his unconventional path to entrepreneurial success, why profit matters more than growth, and much more. Thank you to the sponsors of The Elevate Podcast Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠masterclass.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Framer: ⁠framer.com/elevate⁠ Northwest Registered Agent: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠northwestregisteredagent.com/elevatefree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Homeserve: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠homeserve.com⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

See more here: https://karenswain.com/elevate-2026/ The word woke is used so much on social media, podcasts, interviews and in the news. People use it to attack others who have a different opinion. But what does the work WOKE really mean, what is the origin of the word and who are they attacking. Today on ELEVATE we will discuss this and more.. Please send us your questions and topics you want to covered here: https://karenswain.com/connect/ LINKS; KAren Swain Website: https://karenswain.com/ Kristin Mismash Website: https://www.kristinmismash.com/ ATP- Media: https://karenswain.com/listen/ ELEVATE is a NEW SHOW on UPRN. Live conversations and Q & A with KAren Swain and friends, around the awareness shift waking our quantum realities. Also conversations on HOT topics in the Spiritual and Consciousness genre. Audience participation - Please send in your questions. On today show KAren, Kristin and Carolann will chat about this new show and share stories. #woke #wokeworld #awakening #ascension #consciousness #5dconnection

Mental Skills Coach, Carrie Jackson is back for another episode - we are deep diving into visualization for runners! What it is, why it matters, how to achieve strong visualization in training and racing, the benefits, who can and should practice it, and any drawbacks.For those looking to hear Carrie in the previous Elevate episode, How to Elevate Your Mindset with Mental Skills Coach, Carrie Jackson (ep 189) Carrie has a bunch of offerings: online course called Training the Mental Game: Mindset Coaching Course.https://learning.8020endurance.com/courses/Training-the-Mental-GameShe also offers a free 4 Week Race Day Mindset Plan on TrainingPeaks: https://www.trainingpeaks.com/training-plans/running/tp-579492/4-week-race-day-mindset-plan-mental-skills-for-race-day-free-w-code-8020mindsetHer website is carriejackson.com. Follow her on IG here.Where to Listen:Apple Podcasts | Spotify | Youtube MusicConnect with us:elevateyourrunning.comElevateyourrunning and sayrahrunshappyThe Elevate Coaching Team has  1:1 coaching spots open for spring and fall race season! If you love running and want to get better + faster at this sport, we'd love to have you join our team! You can find more information about our coaching packages at https://elevateyourrunning.com/virtual-coaching or email Sara at sara@elevateyourrunning.comIf you enjoyed this episode, please subscribe, rate, and leave a review! Share your thoughts on how coaching has impacted your journey on social media using #elevateyourrunning. Do you want to be an inclusive insider? Help support the Elevate Your Running Podcast! Get exclusive content, coaching advice, and more through this platform! PARTNER DISCOUNTS AND LINKS:Dynamic Runner:⁠ code SAYRAHRUNSHAPPY for 10% off your subscriptionCheribundi: code ELEVATE for 15% offRNWY: Use Code Elevate15 for 15% off your orderKETONE-IQ: Your post-run recovery ketones can be found hereCozy Zero:  merino wool running clothes! Save 20% with code SARAM20LEVELLE GELS - Save 10% on all natural gels using code HAPPYRUNNING10 

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Contact us and share your opinionJoin Andy and Gandhi as they cover the impact of local and national events in General Practice as we kick off 2026Join Andy and Gandhi for the first update of 2026 in General PracticeWelcome to 2026Waiting for Neighbourhood Guidance???GP suspended after blocking out appointments to collect children???https://www.pulsetoday.co.uk/news/reg... 5m suspensionSpecific facts available if you want to explore thisLinks to public record of the hearingMany suggest sanction is excessiveWe will discuss the issues around itLong hoursLack of flexibilityCulture of not being able to admit or address pressuresTo pick up kids - pressure, child care, culture…Calls to end GP-issued fit notes after 40,000 per day issued in 2025https://www.pulsetoday.co.uk/news/cli... Some 40,000 people were signed off with fit notes each working day last yearCentre for Social Justice (CSJ) estimated 11 million fit notes were issued in 2025 – the majority by GPs. The CSJ recommended fit note responsibility be moved away from ‘overstretched' GPs and into a new Work and Health Service and ‘embed employment and occupational health support at the point of sign-off'. See boxThey also said the total includes fit notes signed off as ‘may be fit for work' as well as ‘not fit for work'.This is despite the Government introducing legislation in 2022 which expanded fit note certification to other professionals such as nurses, physiotherapists, and occupational therapists. Last year, Government-commissioned research found limited take up of healthcare professionals other than GPs writing fit notes since the 2022 reforms.ThoughtsDifficult to treat, maintain relationship, trust whilst enforcing a need to return to work?Move to online consultations removing direct engagement with patients and losing opportunities to support back to work - something thats good for patientsTalk of removing this responsibility from GP s for some timeUsed to be that 3-6m sickness DWP service assessed - this was Boost your triage skills with our dynamic 5-session live webinar course, tailored for primary care clinicians. Led by Dr. Gandalf and Dr. Ed Pooley, this comprehensive training covers all facets of remote patient triage—digital, on-call, and more. Gain practical knowledge, exclusive tips, and direct access to our experts through open Q&A sessions. Elevate your ability to manage primary care challenges effec Subscribe and hear the latest EPIC episode. Join Dr Mike as he shares how to get started and fly using EMIS to make your life easier with this clinical systembit.ly/EMIScourse

In this episode, Dylan and Brett Werner share how they built Elevate Talent Advisors from the ground up, navigating early uncertainty, relying on relationships, and refining a people-first recruiting model. They also offer advice for employers and job seekers on finding the right fit, pursuing passion, and building sustainable careers in a changing market.

☀️ Crypto Gathering Miami 2026: not everyone wants the full conference sprint. That's why there's the Social Pass ($300): welcome drinks, beach party, and Drinks with @RaoulGMI LIVE

Stuck in the same business cycle year after year? Hospitality veteran Donley Ferguson reveals why your annual forecasts keep falling short—and how to break the pattern. After 30+ years watching businesses repeat the same cycles, Donley created the Vortisys Framework. It's not about working harder. It's about elevating with each cycle instead of staying trapped in the loop. In this episode, you'll discover: Why recognizing your pattern is the first step to breaking it The ancient Ouroboros symbol—and how flipping it changes everything How to forecast growth without falling into the same trap Why asking "why" daily strengthens your purpose and your business The critical mistake businesses make when bringing in new leadership If you're tired of hitting the same revenue ceiling or watching your team repeat last year's playbook, this conversation will shift your perspective. Connect with Donley Ferguson on LinkedIn to learn more about the Vortisys Framework and breaking free from cycles that no longer serve you. Grab your Free E-book Work Yourself Happy (Amazon Best Seller) by Dr. Terri Levine here : https://book.terrilevine.com/work-yourself-happy Join us here to deeply connect with our community:  www.heartrepreneurs.com  Subscribe to this podcast on your favorite podcast platform… Apple: https://podcasts.apple.com/us/podcast/live-well-earn-well-for-coaches-consultants/id1585895518  Spotify: https://open.spotify.com/show/5OjsOxN7MqwKio4Ae6vSMQ 

321 - Let's kick off 2026 the way we actually want to run our businesses: with intention, self-trust, and a plan that doesn't require burnout as a personality trait.What to Listen For:Why goals can feel heavyThe identity shift that mattersWhere you want to feel differentUsing feelings as thought cluesYour dream year, without burnoutAre you editing your own dreams?A fast way to find clarityHow vision simplifies decisionsSaying no without guiltWelcoming challenges instead of resistingIf you want 2026 to feel different, it starts with how you think about who you're becoming, what you're building, and what you're willing to anticipate instead of fear. Hit play, grab the four questions, and let's start this year with a mindset that actually supports your growth. And if you want support and structure along the way, come join us inside Elevate.Join Elevate: www.freedomfocusformula.com/elevateMaster the craft of pet photography at the Hair of the Dog Academy - www.hairofthedogacademy.comStop competing on price, sell without feeling pushy, and reach consistently $2,000+ sales in the Freedom Focus Formula - www.freedomfocusformula.comJOIN THE PARTY: Connect with us on Instagram Explore valuable pet photography resources here Discover effective pricing and sales strategies for all portrait photographers. Ready to grow your business? Elevate helps you do just that. Check out our recommended gear and favorite books.

In this energizing New Year's episode, Heather and Nicole kick off the season with bold updates from Elevate, including a brand-new guided curriculum and a daily private podcast to help photographers stay inspired and focused. They dive into the power of belief, consistency, and building confidence by staying close to positive influence. If you've ever doubted yourself or needed a simple framework for success, this episode is your sign to lean into proximity and possibility. Key Takeaways: A new guided Elevate curriculum makes it easier for photographers to grow with as little as one hour per week. Launch of Elevate Daily, a private podcast with 1–5 minute mindset shifts and inspiration to stay aligned. The concept of "proximity to belief" can dramatically improve confidence and outcomes. Members are already reporting major sales wins by shifting how they think, including $5,000+ weeks. Your belief system fuels your success—and if you don't yet have belief, you can borrow it from someone who does. How to Support the Podcast: Subscribe to the podcast on iTunes or wherever you listen to podcasts. Please like, share, and leave a review. If you like the content, please share with your friends by posting on social media so that we can reach and impact more people. Join our next free coaching workshop: www.getcoachedbyheather.com Connect: Heather Lahtinen: Website, Facebook, Instagram

Stefanos Sifandos is a close friend of mine, one of my personal coaches, and the author of the book Tuned In and Turned On. I had the chance to read it before it was released and finished it in less than 48 hours. It felt like he was speaking directly to me the entire time. In this episode, we talk about what it really means to be “tuned in” in your relationship, why so many men unknowingly disconnect through busyness and achievement, and how that disconnection slowly erodes intimacy.Stefanos breaks down how childhood conditioning, shame, and unprocessed pain show up in adult relationships and what men can do differently starting today. We also cover masculine and feminine dynamics, how safety creates attraction, why presence matters more than productivity at home, and the simple daily practices that help men reconnect without losing their edge.This episode is for married men, men in serious relationships, and anyone who wants deeper connection and fulfillment. Get the book + bonuses:TunedInAndTurnedOnBook.comFollow Stefanos:@StefanosSifandosPersonal Site: https://stefanossifandos.com/